| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International plc | Mavrilimumab | Giant cell arteritis (GCA) | Phase 2 | Trial Discontinued | Intravenous | Immunology |
| Kiora Pharmaceuticals Inc. | KIO-101 | Rheumatoid Arthritis | Phase 2 | Trial Discontinued | Oral | Immunology: Anti-TNF |
| Kodiak Sciences Inc | Tarcocimab tedromer (KSI-301) - (GLOW2) | Non-proliferative diabetic retinopathy | Phase 3 | Ongoing | Intravitreal | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (GLIMMER) | Diabetic Macular Edema (DME) | Phase 3 | Data Released | Intravitreal injection | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (DAYLIGHT) | Treatment-Naive Wet Age-Related Macular Degeneration (AMD) | Phase 3 | Trial Completed | Intravitreal | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (GLIMMER) | Diabetic Macular Edema (DME) | Phase 3 | Data Released | Intravitreal injection | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (DAYLIGHT) | Treatment-Naive Wet Age-Related Macular Degeneration (AMD) | Phase 3 | Trial Completed | Intravitreal | Opthalmic |
| Kodiak Sciences Inc | KSI-301 - (BEACON) | Retinal vein occlusion (RVO) | Phase 3 | Data Released | Intravitreal | Opthalmic |